Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Effects of Epigallocatechin-3-gallate on Growth, Epidermal Growth Factor Receptor Signaling Pathways, Gene Expression, and Chemosensitivity in Human Head and Neck Squamous Cell Carcinoma Cell Lines

Muneyuki Masuda, Masumi Suzui and I. Bernard Weinstein
Muneyuki Masuda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masumi Suzui
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. Bernard Weinstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published December 2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Cytotoxic effect of EGCG on YCU-H891 and YCU-N861 cells. Cells were treated with the indicated concentration of EGCG, and the surviving fraction was determined by clonogenic assays. A survival fraction of 1.0 corresponds to the numbers of colonies obtained with control untreated cultures. Each point indicates the average of triplicate dishes; bars, SD.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Effects of EGCG on cell cycle progression and apoptosis. Exponentially growing cells were grown with the indicated concentrations of EGCG and then analyzed by DNA flow cytometry at the indicated time points (A). The distribution of cells in the sub-G1 fraction (apoptosis) and in the G1, S, and G2-M phases of the cell cycle were calculated and plotted (B). An additional separate experiment gave similar results.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Western blot analyses for the p21Cip1, p27Kip1, cyclin D1, pRB, Bcl-2, Bcl-XL, and Bax proteins (A) and for activated caspase 9 protein (B) in extracts of YCU-H891 and YCU-N861 cells. Cells were treated with 10 μg/ml (A) or 50 μg/ml (B) of EGCG for the indicated times, and extracts were prepared. An antibody for actin was used as a loading control (A). The Mr 46,000 and Mr 36,000 caspase 9 protein band represents the inactivated and activated forms of caspase 9, respectively (B). pp-RB, hyperphosphorylated pRB.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Western blot analysis for the EGFR, phosphorylated EGFR (p-EGFR), ERK, phosphorylated ERK (p-ERK), and Stat3 and phosphorylated Stat 3 (p-Stat 3) proteins. Cells were cultured in serum-free medium for 24 h, incubated with or without 10 μg/ml of EGCG for an additional 24 h, and then harvested. For TGF-α stimulation, cells were treated with 50 ng/ml of TGF-α for 6 h (YCU-H891) or for 18 h (YCU-N861) before harvesting. An antibody for actin was used as a loading control.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Reporter assays for c-fos (A) and cyclin D1 (B) in YCU-H891 (left) and YCU-N861 (right) cells. Cells were transfected in opti-MEM I medium with the c-fos promoter-luciferase or cyclin D1 promoter-luciferase reporter plasmids for 16 h and were then cultured in serum-free medium with the indicated concentrations of EGCG for 24 h. For the growth factor stimulation assays, TGF-α was added 30 min after EGCG. Luciferase activities were normalized to parallel assays for β-gal activities; bars, SD.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Cytotoxic effects of the combination of EGCG and 5-FU (A) or of EGCG alone (B) on YCU-H861 and YCU-N861 cells, using cell proliferation assays. Cells were treated with the indicated concentrations of drugs for 48 h, and the extent of inhibition of cell proliferation was determined by proliferation assays (See “Materials and Methods”). A value of 1.0 corresponds to the vehicle-treated control cells; bars, SD.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Cytotoxic effects of EGCG plus 5-FU using colony formation assays with YCU-N861 and YCU-H861 cells. One thousand cells were seeded and cultured for 24 h in 100-mm dishes. The cells were then treated with DMSO alone, with 0.1 μg/ml of EGCG alone, with 5-FU alone, or with 5-FU plus 0.1 μg/ml of EGCG. With YCU-N861 cells, the concentration of 5-FU was 0.1 μg/ml, and with YCU-H891 cells, the concentration of 5-FU was 0.5 μg/ml. The drugs were washed out 48 h later, and the cells were cultured for an additional 7 days. The colonies were then stained with Giemsa solution (A is a photograph of the results obtained with YCU-N861 cells), and the numbers of colonies were counted and plotted as a fraction of the vehicle-treated cultures (B). Each column indicates the average of triplicate dishes; bars, SD. A relative survival of 1.0 corresponds to the control cells; bars, SD.

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    A hypothetical mechanism by which EGCG inhibits growth and induces apoptosis in HNSCCs and thereby synergizes with 5-FU. The EGFR is activated by TGF-α, in an autocrine manner, thus leading to activation of the ras-ERK and Stat3 pathways. The c-fos, cyclin D1, Bcl-XL, and Bcl-2 genes are targets of these signal transduction pathways; therefore, tumor growth is enhanced. EGCG inhibits these signal transduction pathways and thereby induces G1 arrest and apoptosis and potentiates the cytotoxicity of 5-FU.

PreviousNext
Back to top
December 2001
Volume 7, Issue 12
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effects of Epigallocatechin-3-gallate on Growth, Epidermal Growth Factor Receptor Signaling Pathways, Gene Expression, and Chemosensitivity in Human Head and Neck Squamous Cell Carcinoma Cell Lines
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effects of Epigallocatechin-3-gallate on Growth, Epidermal Growth Factor Receptor Signaling Pathways, Gene Expression, and Chemosensitivity in Human Head and Neck Squamous Cell Carcinoma Cell Lines
Muneyuki Masuda, Masumi Suzui and I. Bernard Weinstein
Clin Cancer Res December 1 2001 (7) (12) 4220-4229;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Effects of Epigallocatechin-3-gallate on Growth, Epidermal Growth Factor Receptor Signaling Pathways, Gene Expression, and Chemosensitivity in Human Head and Neck Squamous Cell Carcinoma Cell Lines
Muneyuki Masuda, Masumi Suzui and I. Bernard Weinstein
Clin Cancer Res December 1 2001 (7) (12) 4220-4229;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Articles

  • HER-2/neu Overexpression As a Poor Prognostic Factor for Patients with Metastatic Breast Cancer undergoing High-dose Chemotherapy with Autologous Stem Cell Transplantation
  • Synergistic Chemsensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model
  • Circulating Tumor Cell Clusters in the Peripheral Blood of Colorectal Cancer Patients
Show more Research Articles

Experimental Therapeutics, Preclinical Pharmacology

  • Ring Finger Protein 43 as a New Target for Cancer Immunotherapy
  • ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy
  • Preparation and Biological Evaluation of Copper-64–Labeled Tyr3-Octreotate Using a Cross-Bridged Macrocyclic Chelator
Show more Experimental Therapeutics, Preclinical Pharmacology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement